Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for LXRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 1997. Start Trial.
Date Value
December 31, 2025 -67.85M
December 31, 2024 -180.09M
December 31, 2023 -161.90M
December 31, 2022 -88.85M
December 31, 2021 -87.02M
December 31, 2020 -142.97M
December 31, 2019 113.81M
December 31, 2018 -148.61M
December 31, 2017 -185.39M
December 31, 2016 -175.63M
December 31, 2015 184.78M
December 31, 2014 -75.62M
December 31, 2013 -91.08M
December 31, 2012 -94.46M
December 31, 2011 -87.94M
Date Value
December 31, 2010 -82.37M
December 31, 2009 -89.02M
December 31, 2008 -95.60M
December 31, 2007 -74.32M
December 31, 2006 -56.91M
December 31, 2005 23.44M
December 31, 2004 -42.26M
December 31, 2003 -7.716M
December 31, 2002 -28.79M
December 31, 2001 -17.99M
December 31, 2000 -1.502M
December 31, 1999 -9.615M
December 31, 1998 -6.308M
December 31, 1997 -0.6965M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Viatris, Inc. 2.316B
Pfizer Inc. 11.70B
ANI Pharmaceuticals, Inc. 185.22M
Corcept Therapeutics, Inc. 142.00M
Veru, Inc. -30.04M